Mexico Allergy Therapeutics Market Analysis

Mexico Allergy Therapeutics Market Executive Summary

Mexico Allergy Therapeutics Market was valued at $348 Mn in 2022 and is estimated to reach $582 Mn in 2030, exhibiting a CAGR of 6.65% during the forecast period.

Allergens are harmless substances found in the environment that trigger an immunological reaction. Dust mites, pollen, mold, and commonly consumed food triggers such as milk, eggs, soy, and almonds are common origins of these allergies. These allergies can cause a variety of symptoms, from minor ones like a runny nose and itchy eyes to serious ones like anaphylaxis, which can cause breathing difficulties and even cause a person to lose consciousness. Immunotherapy, avoiding allergens, and using prescription drugs such as antihistamines and nasal corticosteroids are some methods for treating allergies.

The incidence of allergies is a significant health issue in Mexico, where 10%–15% of the population suffers from an allergy of some kind. Among them, allergic rhinitis is the most common, affecting around 10%–15% of people and resulting in symptoms including congestion, itchy eyes, a runny nose, and sneezing that greatly impair quality of life. A further worry is food allergies, which impact 2%–5% of adults and 8%–10% of children. Common allergens include seafood, eggs, cow's milk, peanuts, and almonds. Severe reactions to these allergies frequently call for emergency medical intervention. An estimated 5%–10% of people have skin allergies, with eczema accounting for the majority of cases. Other common skin allergies include hives, contact dermatitis, and medication allergies. Moreover, 8% of Mexicans suffer from respiratory allergies, which include asthma. Mold, dust mites, and pollen are among the triggers that can cause an asthma attack.

A major research project at Mexico's National Institute of Public Health (INSP) is investigating the complex interactions between genetic and environmental factors that lead to the emergence of food allergies in young Mexicans. Finding high-risk populations and possible preventive measures are the main objectives.

Tec de Monterrey is at the forefront of cutting-edge research with the development of oral immunotherapy (OIT) pills that are intended to treat allergies to peanuts. The goal of this research is to provide a more practical and easily available substitute for current peanut allergy therapies.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Allergies: An estimated 10-15% of Mexicans are estimated to be affected by allergies, including food, skin, and respiratory conditions. The prevalence of allergies is thought to be rising, especially in youngsters. The market is expanding due to this increased demand.

Increased Awareness and Diagnosis: More access to healthcare, public health campaigns, and educational programs result in earlier and more accurate allergy diagnoses, which encourage people to seek treatment.

Development of New and Improved Therapies: Technological innovations that provide more effective and customized treatment, such as sublingual immunotherapy (SLIT), targeted monoclonal antibodies for particular illnesses, and personalized medication alternatives, are driving the market.

Market Restraints

Cultural and Behavioural Factors: Market penetration may be hampered by certain groups preference for home remedies or traditional medications over modern therapies. Communities with lower levels of knowledge may take longer to identify and comprehend allergy symptoms, which could result in delayed diagnosis and treatment initiation.

High Cost of Treatment: Due to their high cost, many modern, effective allergy treatments, including biologics and sublingual immunotherapy, are out of reach for a considerable section of the population. This cost barrier may prevent patients from receiving the best care possible and prevent these medicines from being widely used in the market.

Treatment Compliance and Adherence: Consistent commitment to long-term regimens is crucial for the efficacy of allergy treatments, especially immunotherapy therapies. Obstacles including exorbitant expenses, complexity, or unfavourable outcomes resulting in insufficient patient compliance possess the capacity to reduce therapy effectiveness and hinder the market's growth.

Notable Recent Updates:

• August 2022, the FDA has approved Thermo Fisher Scientific's ImmunoCAP blood tests for detecting allergies to wheat and sesame. The company claims that by identifying particular antibodies, in vitro diagnostic tests may distinguish between grass cross-reactivity and wheat sensitization and assist a great number of patients in avoiding needless dietary restrictions.

Healthcare Policies and Regulatory Landscape

Multiple institutions oversee the regulatory control of allergy treatment medications in Mexico, as well as healthcare policy. As the principal regulatory body, the Federal Commission for the Protection against Health Risk COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), is in charge of approving, registering, and supervising drugs after they are sold. Accessibility and distribution of medications used to treat allergies are influenced by healthcare policy defined by the Secretariat of Health. In order to support evidence-based treatment plans, the National Institute of Public Health (INSP) carries out research, including investigations on the genetic and environmental variables causing food allergies. The Comisión Nacional de Bioética (CONBIOÉTICA) oversees ethics, especially in clinical studies. Healthcare organizations that influence access and reimbursement rules include the Mexican Social Security Institute (IMSS), and the Patent Office (IMPI) safeguards intellectual property, which includes patents for novel allergy treatment medications.

Competitive Landscape

Key Players

• GlaxoSmithKline
• Sanofi
• Merck & Co.
• Novartis
• Bayer
• Johnson & Johnson
• Teva Pharmaceutical Industries
• Valeant Pharmaceuticals International
• Grupo farmacéutico Sanfer
• Genomma Laboratorios.